Clinical Trial: Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07781657) titled 'Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease' on Aug. 20.

Brief Summary: This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Alzheimer's Disease

Intervention: DRUG: RO7568282

RO7568282 will be administered as specified in the protocol.

DRUG: Placebo

RO7568282 matching placebo will be administered as specified in the protocol.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hoffmann-La Roche

Disclaimer: Curated by HT Syndication....